B Arun

Summary

Affiliation: The University of Texas
Country: USA

Publications

  1. pmc Phase III randomized trial of dose intensive neoadjuvant chemotherapy with or without G-CSF in locally advanced breast cancer: long-term results
    Banu K Arun
    Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    Oncologist 16:1527-34. 2011
  2. doi request reprint Short-term biomarker modulation prevention study of anastrozole in women at increased risk for second primary breast cancer
    Banu Arun
    Department of Breast Medical Oncology, University of Texas, MD Anderson Cancer Center, Houston, Texas, USA
    Cancer Prev Res (Phila) 5:276-82. 2012
  3. pmc Tissue transglutaminase-induced alterations in extracellular matrix inhibit tumor invasion
    Lingegowda S Mangala
    Department of Experimental Therapeutics, The University of Texas M D Anderson Cancer Center, Houston, Texas, USA
    Mol Cancer 4:33. 2005
  4. pmc Coordinated prophylactic surgical management for women with hereditary breast-ovarian cancer syndrome
    Larissa I Batista
    Department of Surgical Oncology, The University of Texas M, d, Anderson Cancer Center, Houston, TX, USA
    BMC Cancer 8:101. 2008
  5. ncbi request reprint The search for the ideal SERM
    Banu Arun
    Department of Breast Medical Oncology, University of Texas, MD Anderson Cancer Center, Houston, Texas 77030, USA
    Expert Opin Pharmacother 3:681-91. 2002
  6. doi request reprint Response to neoadjuvant systemic therapy for breast cancer in BRCA mutation carriers and noncarriers: a single-institution experience
    Banu Arun
    Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit 1354, Houston, TX 77030 4009, USA
    J Clin Oncol 29:3739-46. 2011
  7. doi request reprint Glutathione-s-transferase-pi expression in early breast cancer: association with outcome and response to chemotherapy
    Banu K Arun
    Departments of Breast Medical Oncology, University of Texas M D Anderson Cancer Center, Houston, USA
    Cancer Invest 28:554-9. 2010
  8. ncbi request reprint Management of women at high risk for breast cancer
    Banu Arun
    Department of Breast Medical Oncology, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    J Natl Compr Canc Netw 1:S71-7. 2003
  9. doi request reprint High prevalence of preinvasive lesions adjacent to BRCA1/2-associated breast cancers
    Banu Arun
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer Prev Res (Phila) 2:122-7. 2009
  10. ncbi request reprint Topoisomerase I inhibition with topotecan: pharmacologic and clinical issues
    B Arun
    University of Texas, MD Anderson Cancer Center, 1515 Holcombe Boulevard, Box 56, Houston, TX 77030, USA
    Expert Opin Pharmacother 2:491-505. 2001

Research Grants

Detail Information

Publications32

  1. pmc Phase III randomized trial of dose intensive neoadjuvant chemotherapy with or without G-CSF in locally advanced breast cancer: long-term results
    Banu K Arun
    Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    Oncologist 16:1527-34. 2011
    ....
  2. doi request reprint Short-term biomarker modulation prevention study of anastrozole in women at increased risk for second primary breast cancer
    Banu Arun
    Department of Breast Medical Oncology, University of Texas, MD Anderson Cancer Center, Houston, Texas, USA
    Cancer Prev Res (Phila) 5:276-82. 2012
    ..Anastrozole is currently being studied as a prevention agent in a large phase III trial and our results provide support for continued evaluation of IGFBP-1 as a surrogate endpoint biomarker in prospective breast chemoprevention studies...
  3. pmc Tissue transglutaminase-induced alterations in extracellular matrix inhibit tumor invasion
    Lingegowda S Mangala
    Department of Experimental Therapeutics, The University of Texas M D Anderson Cancer Center, Houston, Texas, USA
    Mol Cancer 4:33. 2005
    ..Two hundred archived samples from patients with breast cancer were studied for the TG2 expression. Also, in an in vitro model the invasive behavior of MDA-MB-231 cells in the presence or absence of exogenous TG2 was determined...
  4. pmc Coordinated prophylactic surgical management for women with hereditary breast-ovarian cancer syndrome
    Larissa I Batista
    Department of Surgical Oncology, The University of Texas M, d, Anderson Cancer Center, Houston, TX, USA
    BMC Cancer 8:101. 2008
    ..We aimed to assess the feasibility of coordinated PM and BSO in hereditary breast-ovarian cancer syndrome...
  5. ncbi request reprint The search for the ideal SERM
    Banu Arun
    Department of Breast Medical Oncology, University of Texas, MD Anderson Cancer Center, Houston, Texas 77030, USA
    Expert Opin Pharmacother 3:681-91. 2002
    ....
  6. doi request reprint Response to neoadjuvant systemic therapy for breast cancer in BRCA mutation carriers and noncarriers: a single-institution experience
    Banu Arun
    Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit 1354, Houston, TX 77030 4009, USA
    J Clin Oncol 29:3739-46. 2011
    ....
  7. doi request reprint Glutathione-s-transferase-pi expression in early breast cancer: association with outcome and response to chemotherapy
    Banu K Arun
    Departments of Breast Medical Oncology, University of Texas M D Anderson Cancer Center, Houston, USA
    Cancer Invest 28:554-9. 2010
    ..055). Further studies should evaluate the role of GST-pi expression in relation to response to different chemotherapies...
  8. ncbi request reprint Management of women at high risk for breast cancer
    Banu Arun
    Department of Breast Medical Oncology, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    J Natl Compr Canc Netw 1:S71-7. 2003
    ..This review article focuses on risk factors for breast cancer, identification of women at high risk, and the status of preventive strategies...
  9. doi request reprint High prevalence of preinvasive lesions adjacent to BRCA1/2-associated breast cancers
    Banu Arun
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer Prev Res (Phila) 2:122-7. 2009
    ..These findings suggest that BRCA1/2-associated breast cancers progress through the same intermediate steps as sporadic breast cancers, and that DCIS should be considered as a part of the BRCA1/2 tumor spectrum...
  10. ncbi request reprint Topoisomerase I inhibition with topotecan: pharmacologic and clinical issues
    B Arun
    University of Texas, MD Anderson Cancer Center, 1515 Holcombe Boulevard, Box 56, Houston, TX 77030, USA
    Expert Opin Pharmacother 2:491-505. 2001
    ..for 5 days. Current Phase I and Phase II trials are evaluating the combination of topotecan with other chemotherapeutic agents to increase the therapeutic benefits of topotecan. The DLT in these trials is mainly myelosuppression...
  11. ncbi request reprint Endothelin converting enzyme-1 expression in endometrial adenocarcinomas
    B Arun
    Simmons Cancer Center, Division of Hematology and Oncology, University of Texas Southwestern Medical School, Dallas, USA
    Cancer Invest 19:779-82. 2001
    ..With new selective inhibitory molecules emerging, research is currently evaluating the possible inhibition of ECE-1 as an alternative approach for the treatment of endometrial as well as other carcinomas...
  12. ncbi request reprint Comparison of ductal lavage and random periareolar fine needle aspiration as tissue acquisition methods in early breast cancer prevention trials
    Banu Arun
    Breast Medical Oncology, The University of Texas, M D Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 13:4943-8. 2007
    ..The optimum method to retrieve adequate samples and the most accepted method by study participants is not known...
  13. ncbi request reprint Correlation of Bcl-2 and p53 expression in primary breast tumors and corresponding metastatic lymph nodes
    Banu Arun
    Division of Hematology and Oncology, University of Texas Southwestern Medical Center, Dallas, Texas 77030, USA
    Cancer 98:2554-9. 2003
    ..The current study compared Bcl-2 and p53 expression in primary breast carcinoma tissue specimens with Bcl-2 and p53 expression in axillary lymph node specimens...
  14. ncbi request reprint Ductal lavage and risk assessment of breast cancer
    Banu Arun
    The University of Texas MD Anderson Cancer Center, Breast Medical Oncology, 1515 Holcombe Boulevard 424, Houston, Texas 77030, USA
    Oncologist 9:599-605. 2004
    ..This paper reviews breast cancer risk factors, with an emphasis on cytological atypia and the role of ductal lavage in breast cancer risk assessment...
  15. ncbi request reprint Loss of FHIT expression in breast cancer is correlated with poor prognostic markers
    Banu Arun
    Division of Hematology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard 424, Houston, TX 77030, USA
    Cancer Epidemiol Biomarkers Prev 14:1681-5. 2005
    ....
  16. ncbi request reprint Progress in breast cancer chemoprevention
    B Arun
    Department of Breast Medical Oncology, University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Endocr Relat Cancer 9:15-32. 2002
    ..This paper reviews issues related to breast cancer chemoprevention including identification of high risk cohorts, endpoint biomarkers, current and new chemopreventive agents as well as models to evaluate these agents...
  17. ncbi request reprint Prophylactic bilateral salpingo-oophorectomy compared with surveillance in women with BRCA mutations
    Kathleen M Schmeler
    Department of Gynecologic Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas 77230, USA
    Obstet Gynecol 108:515-20. 2006
    ..The objective of this study was to evaluate clinical factors associated with choosing prophylactic bilateral salpingo-oophorectomy (BSO) over surveillance in women with a BRCA1 or BRCA2 mutation...
  18. doi request reprint Knowledge, attitudes, and clinical experience of physicians regarding preimplantation genetic diagnosis for hereditary cancer predisposition syndromes
    Amanda C Brandt
    Department of Gynecologic Oncology, University of Texas M D Anderson Cancer Center, Unit 1362, P O Box 301439, Houston, TX 77230 1439, USA
    Fam Cancer 9:479-87. 2010
    ..Since 68% of physicians had incorrect or limited knowledge of PGD for hereditary cancer, there is a need for additional education...
  19. doi request reprint Clinical application of breast cancer risk assessment models
    Kaylene Ready
    The Univeristy of Texas MD Anderson Cancer Center, Houston, 77030, USA
    Future Oncol 6:355-65. 2010
    ..Their clinical applications are also outlined and clinical situations appropriate for each model are reviewed...
  20. ncbi request reprint Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer
    Aman U Buzdar
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Unit 424, Houston, TX 77030, USA
    J Clin Oncol 23:3676-85. 2005
    ....
  21. pmc Perception of screening and risk reduction surgeries in patients tested for a BRCA deleterious mutation
    Jennifer K Litton
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas, USA
    Cancer 115:1598-604. 2009
    ..Women at a high risk for breast cancer are offered choices for screening or prophylactic surgeries. The aim of this study was to evaluate opinions regarding screening and surgical strategies in high-risk women...
  22. ncbi request reprint Correlation of cytologic findings and chromosomal instability detected by fluorescence in situ hybridization in breast fine-needle aspiration specimens from women at high risk for breast cancer
    Nour Sneige
    Division of Pathology and Laboratory Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Mod Pathol 19:622-9. 2006
    ..Studies evaluating the association between specific patterns of chromosomal polysomy and progression to malignancy may be warranted...
  23. doi request reprint Ductal carcinoma in situ: state of the science and roadmap to advance the field
    Henry M Kuerer
    The University of Texas M D Anderson Cancer Center, DCIS Discovery Program and Department of Surgical Oncology, 1515 Holcombe Blvd, Unit 444, Houston, TX 77030, USA
    J Clin Oncol 27:279-88. 2009
    ..Understanding of the biology and clinical behavior of DCIS is imperfect. This article highlights the current knowledge base and the scientific roadmap needed to advance the field...
  24. doi request reprint Phase 3 study comparing the use of docetaxel on an every-3-week versus weekly schedule in the treatment of metastatic breast cancer
    Edgardo Rivera
    Department of Breast Medical Oncology, University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 112:1455-61. 2008
    ..The varying efficacy results and toxicity profiles noted in these earlier studies led to a comparison of the schedules to determine which was safer and more efficacious...
  25. pmc Collagen IV levels are elevated in the serum of patients with primary breast cancer compared to healthy volunteers
    C Mazouni
    Laboratoire de transfert biologique et oncologique, Marseille University, Houston, TX, USA
    Br J Cancer 99:68-71. 2008
    ..In conclusion, patients with breast cancer have elevated levels of collagen IV compared to healthy women and collagen IV levels increase further during chemotherapy...
  26. doi request reprint Factors affecting the decision of breast cancer patients to undergo contralateral prophylactic mastectomy
    Min Yi
    Department of Surgical Oncology, The University of Texas M D Anderson Cancer Center, Houston, 77030, USA
    Cancer Prev Res (Phila) 3:1026-34. 2010
    ..Evidence-driven models are needed to better inform women of their absolute risk of contralateral breast cancer as well as their competing risk of recurrence from the primary breast cancer to empower them in their active decision making...
  27. doi request reprint Clinical and pathologic characteristics of patients with BRCA-positive and BRCA-negative breast cancer
    Deann P Atchley
    Department of Breast Medical Oncology, Unit 1354, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    J Clin Oncol 26:4282-8. 2008
    ..Mutations in the BRCA1 and BRCA2 genes confer greater risk of developing breast cancer. We determined whether tumor pathologic features and clinical features differ in patients with and without BRCA mutations...
  28. doi request reprint Predictors of contralateral breast cancer in patients with unilateral breast cancer undergoing contralateral prophylactic mastectomy
    Min Yi
    Department of Surgical Oncology, Unit 444, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    Cancer 115:962-71. 2009
    ..The objective of this study was to identify the clinicopathologic factors that predict contralateral breast cancer and thereby inform decisions regarding performing CPM in unilateral breast cancer patients...
  29. ncbi request reprint A single-gene biomarker identifies breast cancers associated with immature cell type and short duration of prior breastfeeding
    W F Symmans
    Department of Pathology, University of Texas MD Anderson Cancer Center, Houston, 77030, USA
    Endocr Relat Cancer 12:1059-69. 2005
    ..036). GABApi gene expression is increased in breast cancers of immature (undifferentiated) cell type and is significantly associated with shorter lifetime history of breastfeeding and with high-grade breast cancer in Hispanic women...
  30. pmc The functional promoter polymorphism (-842G>C) in the PIN1 gene is associated with decreased risk of breast cancer in non-Hispanic white women 55 years and younger
    Chan H Han
    Department of Epidemiology, Unit 1365, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    Breast Cancer Res Treat 122:243-9. 2010
    ..In conclusion, the PIN1 polymorphisms may contribute to the etiology of sporadic breast cancer in non-Hispanic white women 55 years and younger. Further validation in large population-based studies is needed...
  31. doi request reprint IGFBP2 and IGFBP5 overexpression correlates with the lymph node metastasis in T1 breast carcinomas
    Huamin Wang
    Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    Breast J 14:261-7. 2008
    ..Our data suggest that IGFBP2 and IGFBP5 play a role in the development of metastasis and may serve as useful markers to predict lymph node metastasis in patients with small (T1) invasive breast carcinomas...
  32. ncbi request reprint A phase I clinical and pharmacokinetic study of oral CI-1033 in combination with docetaxel in patients with advanced solid tumors
    Linda L Garland
    Arizona Cancer Center, University of Arizona, Tucson, Arizona 85724, USA
    Clin Cancer Res 12:4274-82. 2006
    ..We conducted a dose escalation study of CI-1033 with docetaxel to assess the safety profile and pharmacokinetics of the combination and to establish the maximum tolerated dose...

Research Grants1

  1. Biomarker modulation/COX-2 inhibitor/Breast Cancer
    Banu Arun; Fiscal Year: 2003
    ..Ultimately, the development of non-hormonal chemoprevention agents, and identification of surrogate markers will allow us to plan large-scale, phase III chemoprevention studies with the endpoint of cancer incidence. ..